SIREN : 800073306
SPFPL METPHARMA is a French company founded 12 years ago, specialized in the sector Activités des sociétés holding. Based in SAINT-SAUVEUR (70300), this company of category PME shows in 2024 a net income negative of -4 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
| Net income | -3 851 € | 33 467 € | 33 708 € | 32 207 € | 31 690 € | 18 484 € | 27 280 € | 28 438 € | 28 431 € |
| EBITDA | -2 418 € | -2 550 € | -2 429 € | -2 504 € | -2 361 € | -1 024 € | 2 602 € | -3 187 € | -3 215 € |
| Net margin | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
In 2024, SPFPL METPHARMA records a net loss of 4 k€. This deficit will reduce equity on the balance sheet.
-2 418 €
-2 418 €
-3 851 €
The debt ratio (= Financial debt / Equity x 100) stands at 13%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 87%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
12.674%
87.17%
-20.047
In 2024, the debt ratio of SPFPL METPHARMA (12.67) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of SPFPL METPHARMA (87.2%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of SPFPL METPHARMA (-20.05) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 4.61. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 2.1x. Financial charges are adequately covered by operations.
4.61
2.109
In 2024, the liquidity ratio of SPFPL METPHARMA (4.61) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of SPFPL METPHARMA (2.1x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 316 days. Excellent situation: suppliers finance 316 days of the operating cycle (retail model).
0 €
0 j
316 j
0 j
Compare SPFPL METPHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of SPFPL METPHARMA is not publicly disclosed (confidential accounts filed with INPI).
SPFPL METPHARMA recorded a net loss in 2024.
The headquarters of SPFPL METPHARMA is located in SAINT-SAUVEUR (70300), in the department Haute-Saone.
The tax return of SPFPL METPHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SPFPL METPHARMA operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.